**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 45954

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Surgical resection of gastric stump cancer following proximal gastrectomy for** **adenocarcinoma of the esophagogastric junction**

Ma FH *et al*. Gastric stump cancer following proximal gastrectomy

Fu-Hai Ma, Li-Yan Xue, Ying-Tai Chen, Wei-Kun Li, Yang Li, Wen-Zhe Kang, Yi-Bin Xie, Yu-Xin Zhong, Quan Xu, Yan-Tao Tian

**Fu-Hai Ma, Ying-Tai Chen, Wei-Kun Li, Yang Li, Wen-Zhe Kang, Yi-Bin Xie, Yu-Xin Zhong, Quan Xu, Yan-Tao Tian,** Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

**Li-Yan Xue,** Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

**ORCID number:** Fu-Hai Ma (0000-0003-2437-6881); Li-Yan Xue (0000-0001-5185-0126); Wei-Kun Li ([0000-0002-3883-1497](http://orcid.org/0000-0002-3883-1497)); Ying-Tai Chen (0000-0003-4980-6315); Yang Li ([0000-0002-4549-7087](http://orcid.org/0000-0002-4549-7087)); Wen-Zhe ([0000-0001-9965-8109](http://orcid.org/0000-0001-9965-8109)); Yi-Bin Xie (0000-0002-7887-1389); Yu-Xin Zhong (0000-0002-8865-3297); Quan Xu (0000-0001-9246-3253); Yan-Tao Tian (0000-0001-6479-7547).

**Author contributions:** Tian YT and Xue LY designed the research; Ma FH, Li WK and Chen YT analyzed the data and wrote the paper; Li Y, Kang WZ, Xie YB, Zhong YX and Xu Q collected the patient’s clinical data.

**Supported by** National Natural Science Foundation of China, No. 81772642; Beijing Municipal Science and Technology Commission, No. Z161100000116045; and Capital’s Funds for Health Improvement and Research, CFH 2018-2-4022.

**Institutional review board statement:** This study was approved by the Institutional Review Board of the National Cancer Center Hospital.

**Informed consent statement:** The need for informed consent was waived due to the retrospective nature of the study, and the data were anonymously analyzed.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Corresponding author: Yan-Tao Tian, MD, Professor,** Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Beijing 100021, China. tyt67@163.com

**Telephone:** +86-10-87787120

**Fax: +**86-10-87787120

**Received:** January 23, 2019

**Peer-review started:** January 23, 2019

**First decision:** March 14, 2019

**Revised:** April 1, 2019

**Accepted:** April 19, 2019

**Article in press:** April 19, 2019

**Published online:** May 15, 2019

**Abstract**

***BACKGROUND***

Proximal gastrectomy (PG) is performed widely as a function-preserving operation for early gastric cancer located in the upper third of the stomach and is an important function-preserving approach for esophagogastric junction (EGJ) adenocarcinoma. The incidence of gastric stump cancer (GSC) after PG is increasing. However, little is known about the GSC following PG because very few studies have been conducted on the disease.

***AIM***

To clarify clinicopathologic features, perioperative complications, and long-term survival rates after resection of GSC following PG.

***METHODS***

Data for patients with GSC following PG for adenocarcinoma of the EGJ diagnosed between January 1998 and December 2016 were retrospectively reviewed. Multivariate analysis was performed to identify factors associated with overall survival (OS). GSC was defined in accordance with the Japanese Gastric Cancer Association.

***RESULTS***

A total of 35 patients were identified. The median interval between the initial PG and resection of GSC was 4.9 (range 0.7-12) years. In 21 of the 35 patients, the tumor was located in a nonanastomotic site of the gastric stump. Total gastrectomy was performed in 27 patients; the other 8 underwent partial gastrectomy. Postoperative complications occurred in 6 patients (17.1%). The tumor stage according to the depth of tumor invasion was T1 in 6 patients, T2 in 3 patients, T3 in 9 patients, and T4 in 17 patients. Lymph node metastasis was observed in 18 patients. Calculated 1-, 3-, and 5-year OS rates were 86.5%, 62.3%, and 54.2%, respectively. Multivariate analysis showed advanced T stage to be associated with OS.

***CONCLUSION***

This study reveals the characteristics of GSC following PG for adenocarcinoma of the EGJ and suggests that a surgical approach can lead to a satisfactory outcome.

**Key words:** Gastric stump cancer; Proximal gastrectomy; Esophagogastric junction; Distal gastrectomy

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The clinicopathological characteristics, treatment, and prognosis of gastric stump cancer (GSC) after distal gastrectomy have been well investigated, however, there is limited information on GSC after proximal gastrectomy (PG). We revealed characteristics of GSC in detail using the largest number of patients to date. Our results suggest that surgical approaches can achieve satisfactory outcomes in GSC following PG. The factor associated with OS based on multivariate analysis was advanced T stage and GSC is more likely to be diagnosed at an advanced stage. Thus, endoscopic follow-up of the gastric stump should be conducted to detect GSC at an early stage.

Ma FH, Xue LY, Chen YT, Li WK, Li Y, Kang WZ, Xie YB, Zhong YX, Xu Q, Tian YT. Surgical resection of gastric stump cancer following proximal gastrectomy for adenocarcinoma of the esophagogastric junction. *World J Gastrointest Oncol* 2019; 11(5): 416-423

**URL:** https://www.wjgnet.com/1948-5204/full/v11/i5/416.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v11.i5.416

**INTRODUCTION**

Although the prevalence of gastric cancer is decreasing, the incidence of esophagogastric junction (EGJ) adenocarcinoma is increasing[1]. The choice of surgical techniques for EGJ adenocarcinoma is controversial, yet proximal gastrectomy (PG) remains an important surgical option[2,3]. PG is also widely used as a function-preserving approach for early-stage proximal stomach cancer[4]. The incidence of gastric stump cancer (GSC) after PG is growing[5-8], and GSC following PG may thus be increasingly encountered by surgeons in the coming years.

The clinicopathological characteristics, treatment, and prognosis of GSC after distal gastrectomy (DG) have been well investigated[9-11]; however, there is limited information on GSC after PG. To our knowledge, there are only few studies have been published on GSC following PG[8,12,13]. As such, we conducted a single-center retrospective study to understand the associated clinicopathological features, surgical results and long-term outcomes of GSC following PG.

**MATERIALS AND METHODS**

This retrospective study was approved by the Institutional Review Board of Cancer Hospital of the Chinese Academy of Medical Sciences and was based on demographic and pathological data retrieved from a computerized database of all patients with gastric cancer treated at this facility between January 1998 and December 2016. The need for informed consent was waived due to the retrospective nature of the study, and the data were anonymously analyzed.

PG or PG plus esophagectomy followed by esophagogastrostomy reconstruction are usually indicated for EGJ adenocarcinoma and gastric cancer located in the upper third of the stomach. We defined GSC according to the Japanese Classification and Treatment Guidelines for Gastric Cancer (14th edition), in which GSC is defined as a cancer arising in the gastric stump after gastrectomy, regardless of the histology of the previous lesion (benign or malignant), risk of recurrence, extent of initial resection, or method of reconstruction[14]. Thirty-five patients who had undergone resection of the gastric stump for GSC following PG at Cancer Hospital of the Chinese Academy of Medical Sciences were eligible for inclusion in the study. We reviewed GSC after PG for adenocarcinoma of the EGJ in terms of the time to treatment of GSC, pathological findings of GSC, postoperative outcomes and long-term results.

To investigate whether the time interval significantly influenced survival, we divided the patients into 2 groups: interval < 5 years (*n* = 21) and ≥ 5 years (*n* = 14). We also divided the patients into 2 groups to investigate whether the tumor location significantly impacted survival: tumors located in anastomotic sites (*n* = 14) and tumors located in nonanastomotic sites (*n* = 20). Medical records were reviewed with regard to preoperative medical conditions, perioperative complications, histopathological results and follow-up data.

***Statistical analysis***

Cumulative survival rates were obtained using the Kaplan–Meier method and compared using the log-rank test to evaluate statistically significant differences. Cox proportional hazards regression analysis was used to evaluate factors affecting overall survival (OS). P < 0.05 was considered significant. The statistical analysis was performed with SPSS for Windows version 22.0.

**RESULTS**

***Patients and clinical characteristics***

The demographic and clinical characteristics of 35 patients with GSC following PG are shown in Table 1. The mean age was 60 ± 11 years, and the male-to-female ratio was 7.75 to 1. Of the 35 patients, the mean interval between primary PG and the development of GSC was 4.9 (range 0.7-12) years. The time to treatment of GSC was within 5 years in 21 patients, within 5–10 years in 10 patients, and longer than 10 years in 4 patients. Regarding the initial EGJ adenocarcinoma, 2 patients had type I, 29 had type II, and 4 had type III disease according to Siewert Classification. All of the patients underwent PG with esophagogastrostomy. With regard to the site of tumors in the gastric stump, 14 and 21 were in anastomotic and nonanastomotic sites, respectively.

***Surgical characteristics and short-term outcomes***

Total gastrectomy as the primary procedure for GSC was performed in 27 patients (77.1%) of all patients; partial resection of the gastric remnant was performed in 8 patients (22.9%). In 5 patients, resection of one or more adjacent organs was performed together with gastrectomy. The mean operation time was 343 ± 132 min. The mean intraoperative blood loss volume was 513 ± 383 ml. Postoperative complications were detected in 6 patients (17.1%): 4 patients developed leakage from the anastomotic site, 1 developed wound infection, 1 developed hemorrhage, and 1 developed postoperative ileus. However, none of these patients died (Table 2).

***Histopathological characteristics***

Histological analysis revealed 26 adenocarcinomas and 9 adenocarcinomas with signet ring cells. Analysis of histological differentiation revealed 3 well-differentiated tumor types, 11 moderately differentiated tumor types, and 21 poorly differentiated tumor types. The disease stage according to the depth of tumor invasion was T1 in 6 patients, T2 in 3 patients, T3 in 9 patients, T4a in 11 patients, and T4b in 6 patients. The median number of dissected lymph nodes was 11.1 ± 7.4, and the median number of lymph node metastases was 2.9 ± 4.2. Lymph node metastasis was observed in 18 patients (Table 3).

***Long-term outcomes and factors affecting survival***

The 1-, 3-, and 5-year OS rates were 86.5%, 62.3%, and 54.2%, respectively. The results of the Cox proportional hazards model demonstrated T stage to be a significant independent prognostic factor for survival (Table 4). The 5-year survival rates for patients with T1/T2, T3 and T4 disease were 85.7%, 72.0% and 30.6%, respectively.

**DISCUSSION**

GSC was originally defined as gastric cancer occurring at least five years after after DG for benign disease[15,16]. Recently, GSC has been used to refer to all cancers detected in the gastric stump, irrespective of the primary disease or initial operation[17]. The incidence of GSC following PG is increasing, and that of GSC is reportedly higher after PG (3.6%–9.1%) than after DG (0.4%–2.5%)[18]. Moreover, Nozaki *et al*[19] found that PG is an independent risk factor for GSC. Compared to DG, PG may result in an additional risk for GSC[11]. Surgery, pathogenesis, and prognosis of GSC after DG are well investigated; however, little is known about GSC following PG because very few studies have been conducted on the disease. To the best of our knowledge, this is the first study investigating GSC following PG for EGJ adenocarcinoma.

Resection of GSC is associated with intra-abdominal adhesion after the initial procedure. Surgeons sometimes encounter technical difficulties during resection, which leads to prolonged operation time and excessive blood loss. Furthermore, intraoperative surgical complications, such as intestinal injury, may occur. Previous studies have reported an overall surgical complication rate of 19%-47% for GSC, with operation-related mortality rates of 2%-13%[20]. However, little is known about the complication rate of GSC following PG. In our study, the overall complication rate was 17.1%, which is relatively low. Additionally, 5 of 35 patients (14.3%) required additional organ resection; this rate is also lower than that reported for GSC after DG[21]. The need for additional organ resection may complicate surgery in patients with GSC.

Ohyama *et al*[12] identified almost the same numbers of differentiated and undifferentiated tumors in GSC. However, in our study, 20 of 35 tumors were poorly differentiated. Because only a few studies have been published on the pathological type of GSC, the characteristics of this disease remain unclear. In the present study, early GSC was diagnosed in 6 (17%) of 35 patients, whereas T4 disease was identified in 17 (48.6%). As GSC is more likely to be diagnosed at an advanced stage, endoscopic follow-up of the gastric stump is necessary to detect GSC at an early stage. The incidence of metastasis to lymph nodes was 54.3% (19/35) in the present study, which is higher than that of GSC after DG[11].

Although the number of patients in our study was small, the results showed a 5-year OS rate of 52.8%. In addition, the results of the Cox proportional hazards model showed only T stage to be a significantly independent prognostic factor for survival. In contrast, the time interval or location did not affect survival, which may partly justify the definition of GSC, whereby time interval, tumor location and method of reconstruction are not considered.

Nevertheless, this study has several limitations. First, because not all patients in our study underwent PG at Cancer Hospital of the Chinese Academy of Medical Sciences, some important information on the initial operation was missing, such as the extent of lymphadenectomy, histology type, and pathologic stage. Second, the number of patients enrolled was small, mostly because of the rarity of the disease. Third, there is no standardized definition of GSC, which make our study not able to be accurately compared with previous studies on GSC.

Here, we reveal characteristics of GSC following PG in detail with the largest number of patients to date. Our results suggest that surgical approaches can achieve satisfactory outcomes in GSC following PG, similar to those in patients with typical gastric cancer. GSC is more likely to be diagnosed at an advanced stage, and thus, endoscopic follow-up of the gastric stump should be conducted to detect GSC at an early stage. Further larger-scale studies are necessary to clarify the characteristics of the disease.

PG is performed widely as a function-preserving operation for early gastric cancer located in the upper third of the stomach and is an important function-preserving approach for EGJ adenocarcinoma. The incidence of GSC.

**ARTICLE HIGHLIGHTS**

***Research background***

Proximal gastrectomy (PG) is performed widely as a function-preserving operation for early gastric cancer located in the upper third of the stomach and is an important function-preserving approach for esophagogastric junction (EGJ) adenocarcinoma. The incidence of gastric stump cancer (GSC) after PG is increasing. However, little is known about the GSC following PG because very few studies have been conducted on the disease. To our knowledge, there are only few studies have been published on GSC following PG.

***Research motivation***

The clinicopathological characteristics, treatment, and prognosis of GSC after distal gastrectomy have been well investigated; however, there is limited information on GSC after PG. As such, we conducted a single-center retrospective study to understand the associated clinicopathological features, surgical results and long-term outcomes of GSC following PG.

***Research objectives***

The aim of this study is to clarify clinicopathologic features, perioperative complications, and long-term survival rates after resection of GSC following PG. We revealed characteristics of GSC following PG in detail with the largest number of patients to date. Our results suggest that surgical approaches can achieve satisfactory outcomes in GSC following PG, similar to those in patients with typical gastric cancer. Further larger-scale studies are necessary to clarify the characteristics of the disease.

***Research methods***

This is a retrospective study. Thirty-five patients who had undergone resection of the gastric stump for GSC following PG at Cancer Hospital of the Chinese Academy of Medical Sciences were eligible for inclusion in the study. Medical records were reviewed with regard to preoperative medical conditions, perioperative complications, histopathological results and follow-up data. Cumulative survival rates were obtained using the Kaplan–Meier method and compared using the log-rank test to evaluate statistically significant differences. Cox proportional hazards regression analysis was used to evaluate factors affecting overall survival (OS).

***Research results***

This study reveals the characteristics of GSC following PG for adenocarcinoma of the EGJ and suggests that a surgical approach can lead to a satisfactory outcome. GSC is more likely to be diagnosed at an advanced stage, and thus, endoscopic follow-up of the gastric stump should be conducted to detect GSC at an early stage. Further larger-scale studies are necessary to clarify the characteristics of the disease.

***Research conclusions***

We revealed the characteristics of GSC following PG for adenocarcinoma of the EGJ and suggests that a surgical approach can lead to a satisfactory outcome. GSC is more likely to be diagnosed at an advanced stage, and thus, endoscopic follow-up of the gastric stump should be conducted to detect GSC at an early stage. The incidence of GSC after PG is increasing. Surgical approach can lead to a satisfactory outcome. This is the first study investigating GSC following PG for EGJ adenocarcinoma. GSC following PG should be compared with initial distal gastric cancer. We defined GSC according to the Japanese Classification and Treatment Guidelines for Gastric Cancer (14th edition). Our results suggest that surgical approaches can achieve satisfactory outcomes in GSC following PG, similar to those in patients with typical gastric cancer. There are only few studies have been published on GSC following PG. This study reveals the characteristics of GSC following PG for adenocarcinoma of the EGJ. Endoscopic follow-up of the gastric stump should be conducted to detect GSC at an early stage. Surgical approach should be performed for patients with GSC following PG.

***Research perspectives***

The factor associated with OS based on multivariate analysis was advanced T stage and GSC is more likely to be diagnosed at an advanced stage. Thus, endoscopic follow-up of the gastric stump should be conducted to detect GSC at an early stage.

**REFERENCES**

1 **Masuzawa T**, Takiguchi S, Hirao M, Imamura H, Kimura Y, Fujita J, Miyashiro I, Tamura S, Hiratsuka M, Kobayashi K, Fujiwara Y, Mori M, Doki Y. Comparison of perioperative and long-term outcomes of total and proximal gastrectomy for early gastric cancer: a multi-institutional retrospective study. *World J Surg* 2014; **38**: 1100-1106 [PMID: 24310733 DOI: 10.1007/s00268-013-2370-5]

2 **Jemal A**, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev* 2010; **19**: 1893-1907 [PMID: 20647400 DOI: 10.1158/1055-9965.EPI-10-0437]

3 **Sugoor P**, Shah S, Dusane R, Desouza A, Goel M, Shrikhande SV. Proximal gastrectomy versus total gastrectomy for proximal third gastric cancer: total gastrectomy is not always necessary. *Langenbecks Arch Surg* 2016; **401**: 687-697 [PMID: 27143021 DOI: 10.1007/s00423-016-1422-3]

4 **Ohashi M**, Morita S, Fukagawa T, Oda I, Kushima R, Katai H. Functional Advantages of Proximal Gastrectomy with Jejunal Interposition Over Total Gastrectomy with Roux-en-Y Esophagojejunostomy for Early Gastric Cancer. *World J Surg* 2015; **39**: 2726-2733 [PMID: 26253640 DOI: 10.1007/s00268-015-3180-8]

5 **Nozaki I**, Kurita A, Nasu J, Kubo Y, Aogi K, Tanada M, Takashima S. Higher incidence of gastric remnant cancer after proximal than distal gastrectomy. *Hepatogastroenterology* 2007; **54**: 1604-1608 [PMID: 17708311 DOI: 10.1016/j.jafrearsci.2005.08.003]

6 **Nunobe S**, Ohyama S, Miyata S, Matsuura M, Hiki N, Fukunaga T, Seto Y, Ushijima M, Yamaguchi T. Incidence of gastric cancer in the remnant stomach after proximal gastrectomy. *Hepatogastroenterology* 2008; **55**: 1855-1858 [PMID: 19102408 DOI: 10.1136/gut.2007.129296corr1]

7 **Nozaki I**, Nasu J, Kubo Y, Tanada M, Nishimura R, Kurita A. Risk factors for metachronous gastric cancer in the remnant stomach after early cancer surgery. *World J Surg* 2010; **34**: 1548-1554 [PMID: 20217411 DOI: 10.1007/s00268-010-0518-0]

8 **Iwata Y**, Ito S, Misawa K, Ito Y, Komori K, Abe T, Shimizu Y, Tajika M, Niwa Y, Yoshida K, Kinoshita T. Incidence and treatment of metachronous gastric cancer after proximal gastrectomy. *Surg Today* 2018; **48**: 552-557 [PMID: 29460126 DOI: 10.1007/s00595-018-1632-0]

9 **Tanigawa N**, Nomura E, Lee SW, Kaminishi M, Sugiyama M, Aikou T, Kitajima M; Society for the Study of Postoperative Morbidity after Gastrectomy. Current state of gastric stump carcinoma in Japan: based on the results of a nationwide survey. *World J Surg* 2010; **34**: 1540-1547 [PMID: 20182716 DOI: 10.1007/s00268-010-0505-5]

10 **Honda S**, Bando E, Makuuchi R, Tokunaga M, Tanizawa Y, Kawamura T, Sugiura T, Kinugasa Y, Uesaka K, Terashima M. Effects of initial disease status on lymph flow following gastrectomy in cases of carcinoma in the remnant stomach. *Gastric Cancer* 2017; **20**: 457-464 [PMID: 27638289 DOI: 10.1007/s10120-016-0640-2]

11 **Shimada H**, Fukagawa T, Haga Y, Oba K. Does remnant gastric cancer really differ from primary gastric cancer? A systematic review of the literature by the Task Force of Japanese Gastric Cancer Association. *Gastric Cancer* 2016; **19**: 339-349 [PMID: 26667370 DOI: 10.1007/s10120-015-0582-0]

12 **Ohyama S**, Tokunaga M, Hiki N, Fukunaga T, Fujisaki J, Seto Y, Yamaguchi T. A clinicopathological study of gastric stump carcinoma following proximal gastrectomy. *Gastric Cancer* 2009; **12**: 88-94 [PMID: 19562462 DOI: 10.1007/s10120-009-0502-2]

13 **Nozaki I**, Hato S, Kurita A. A new technique for resecting gastric remnant cancer after proximal gastrectomy with jejunal interposition. *Surg Today* 2012; **42**: 1135-1138 [PMID: 22688565 DOI: 10.1007/s00595-012-0212-y]

14 **Sano T**, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. *Gastric Cancer* 2011; **14**: 97-100 [PMID: 21573921 DOI: 10.1007/s10120-011-0040-6]

15 **Di Leo A**, Pedrazzani C, Bencivenga M, Coniglio A, Rosa F, Morgani P, Marrelli D, Marchet A, Cozzaglio L, Giacopuzzi S, Tiberio GA, Doglietto GB, Vittimberga G, Roviello F, Ricci F. Gastric stump cancer after distal gastrectomy for benign disease: clinicopathological features and surgical outcomes. *Ann Surg Oncol* 2014; **21**: 2594-2600 [PMID: 24639193 DOI: 10.1245/s10434-014-3633-6]

16 **Yajima K**, Iwasaki Y, Yuu K, Oohinata R, Amaki M, Kohira Y, Natsume S, Ishiyama S, Takahashi K. A Case of Laparoscopic Resection for Carcinoma of the Gastric Remnant following Proximal Gastrectomy Reconstructed with Jejunal Interposition. *Case Rep Surg* 2016; **2016**: 9357659 [PMID: 27034881 DOI: 10.1155/2016/9357659]

17 **Morgagni P**, Gardini A, Marrelli D, Vittimberga G, Marchet A, de Manzoni G, Di Cosmo MA, Rossi GM, Garcea D, Roviello F; Italian Research Group for Gastric Cancer. Gastric stump carcinoma after distal subtotal gastrectomy for early gastric cancer: experience of 541 patients with long-term follow-up. *Am J Surg* 2015; **209**: 1063-1068 [PMID: 25218580 DOI: 10.1016/j.amjsurg.2014.06.021]

18 **Nunobe S**, Hiki N. Function-preserving surgery for gastric cancer: current status and future perspectives. *Transl Gastroenterol Hepatol* 2017; **2**: 77 [PMID: 29034350 DOI: 10.21037/tgh.2017.09.07]

19 **Nozaki I**, Hato S, Kobatake T, Ohta K, Kubo Y, Nishimura R, Kurita A. Incidence of metachronous gastric cancer in the remnant stomach after synchronous multiple cancer surgery. *Gastric Cancer* 2014; **17**: 61-66 [PMID: 23624766 DOI: 10.1007/s10120-013-0261-y]

20 **Kwon IG**, Cho I, Choi YY, Hyung WJ, Kim CB, Noh SH. Risk factors for complications during surgical treatment of remnant gastric cancer. *Gastric Cancer* 2015; **18**: 390-396 [PMID: 24705942 DOI: 10.1007/s10120-014-0369-8]

21 **Takahashi M**, Takeuchi H, Tsuwano S, Nakamura R, Takahashi T, Wada N, Kawakubo H, Saikawa Y, Kitagawa Y. Surgical Resection of Remnant Gastric Cancer Following Distal Gastrectomy: A Retrospective Clinicopathological Study. *Ann Surg Oncol* 2016; **23**: 511-521 [PMID: 26104543 DOI: 10.1245/s10434-015-4678-x]

**P-Reviewer:** Faloppi L, Lee S **S-Editor:** Ji FF **L-Editor:** A **E-Editor:** Wu YXJ

**Specialty type:** Oncology

**Country of origin:** China

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Clinical characteristics of patients**

|  |  |  |
| --- | --- | --- |
| **Characteristics** | | **Number of patients (%)** |
| Sex | Male | 31 (88.6) |
|  | Female | 4 (11.4) |
| Age (yr) |  | 60 ± 11 (33-83) |
| ASA | Ⅰ-Ⅱ | 25 (71.4) |
|  | Ⅲ-Ⅳ | 10 (28.6) |
| Comorbidity | Any comorbidity | 7 (20) |
|  | Hypertension | 2 (5.7) |
|  | Diabetes | 1 (2.9) |
|  | COPD | 1 (2.9) |
|  | Coronary artery disease | 2 (5.7) |
|  | Cerebral vascular disease | 1 (2.9) |
| Family history of gastric cancer |  | 4 (11.8) |
| Siewert type of initial  EGJ adenocarcinoma | SiewertⅠ | 2 (5.7) |
|  | Siewert Ⅱ | 29 (82.9) |
|  | Siewert Ⅲ | 4 (11.4) |
| Adjuvant therapy after initial operation | Received | 17 (48.6) |
|  | Not received | 4 (11.4) |
|  | Unknown | 14 (40) |
| Tumor location | Anastomotic site | 14 (40) |
|  | Nonanastomotic site | 21 (60) |
| Interval (yr) |  | 4.9 ± 3.2 (0.7-12) |
| Interval | < 5 yr | 21 (60) |
|  | ≥ 5 yr, < 10 yr | 10 (28.6) |
|  | ≥ 10 yr | 4 (11.4) |

COPD: Chronic obstructive pulmonary disease; EGJ: Esophagogastric junction.

**Table 2 Surgical characteristics and short-term outcomes**

|  |  |  |
| --- | --- | --- |
| **Surgical characteristics** | | **Number of patients (%)** |
| Operation type | Total gastrectomy | 27 (77.1) |
|  | Partial gastrectomy | 8 (22.9) |
| Additional organ resection | Yes | 5 (14.3) |
|  | Yes | 5 (14.3) |
| Estimated blood loss (mL) |  | 513 ± 383 |
| Operation time (min) |  | 343 ± 132 |
| Blood transfusion | No | 9 (25.7) |
|  | Yes | 26 (74.3) |
| Postoperative complications | Any complication | 6 (17.1) |
|  | Leakage | 4 (11.4) |
|  | Hemorrhage | 1 (2.9) |
|  | Ileus | 1 (2.9) |
|  | Wound infection | 1 (2.9) |
| Postoperative hospital stay (d) |  | 18.4 ± 12.1 |

**Table 3 Histopathological characteristics**

|  |  |  |
| --- | --- | --- |
| **Pathological characteristics** | | **Number of patients (%)** |
| Histology | Adenocarcinoma | 26 (74.3) |
|  | Adenocarcinoma with signet ring cell | 9 (25.7) |
| Pathologic grade | Poor | 21 (60.0) |
|  | Moderate | 11 (31.4) |
|  | Well | 3 (8.6) |
| T stage | T1a-1b | 6(17.1) |
|  | T2 | 3 (8.6) |
|  | T3 | 9 (25.7) |
|  | T4a | 11 (31.5) |
|  | T4b | 6 (17.1) |
| Number of dissected lymph nodes |  | 11.1 ± 7.4 |
| Number of lymph node metastasis |  | 2.9 ± 4.2 |
| N stage | N0 | 16 (45.7) |
|  | N1/N2/N3 | 19 (54.3) |

**Table 4 Univariate and Multivariate analyses of clinicopathologic factors associated with overall survival**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **5-yr OS (%)** | **Univariate** | | **Multivariate** | |
| **Hazard ratio** | ***P* value** | **Hazard ratio** | ***P* value** |
| Sex: Male *vs* female | 49.4 *vs* 66.7 | 0.298 (0.037-2.381) | 0.229 | - | - |
| Age: < 65 yr *vs* ≥ 65 yr | 63.5 *vs* 44.7 | 0.359 (0.557-5.035) | 0.354 | - | - |
| Tumor location: Anastomotic *vs* nonanastomotic | 57.7 *vs* 56.2 | 1.151 (0.351-3.774) | 0.816 | - | - |
| Interval: < 5 yr *vs* ≥ 5 yr | 56.8 *vs* 55.4 | 0.665 (0.213-2.074) | 0.479 | - | - |
| Operation type: Completion gastrectomy *vs* segmental resection | 56.2 *vs* 68.6 | 0.473 (0.104-2.155) | 0.323 | - | - |
| Histology: Adenocarcinoma *vs* adenocarcinoma with signet ring cell | 65.6 *vs* 0 | 2.714 (0.766-9.616) | 0.108 | 0.376 (0.098-1.44) | 0.154 |
| Pathologic grade: Poor *vs* moderate/well | 49.7 *vs* 65.3 | 0.812 (0.264-2.493) | 0.715 | - | - |
| T stage: T1-3 *vs* T4 | 77.0 *vs* 30.6 | 6.954 (1.871-25.848) | **0.001** | 0.166 (0.041-0.672) | **0.012** |
| N stage: N0 *vs* N+ | 73.8 *vs* 39.2 | 4.631 (1.239-17.305) | **0.013** | 0.432 (0.103-1.822) | 0.253 |

OS: Overall survival.